Concepedia

Jonathan T. Seal

JT

Statistics

Publications

10

Citations

737

H-Index

10

Active since

2011

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (Germany)

GlaxoSmithKline (France)

Jonathan T. Seal is an author at GlaxoSmithKline (United Kingdom) specializing in bromodomain proteins, medicinal chemistry, and drug discovery.

ORCID

Publications per year

2011–2022

10

Publications

10

Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)

Jonathan T. Seal, Yann Lamotte, Frédéric Donche et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 213 citations · Full text

, , +16

Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides

Paul Bamborough, Hawa Diallo, Jonathan D. Goodacre et al. · Journal of Medicinal Chemistry · 2011 · 176 citations · Full text

, , +17

From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151

Olivier Mirguet, Yann Lamotte, Frédéric Donche et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 118 citations · Full text

, , +6

The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor

Jonathan T. Seal, Stephen J. Atkinson, Helen Aylott et al. · Journal of Medicinal Chemistry · 2020 · 63 citations · Full text

, , +14

Design and Synthesis of a Highly Selective and <i>In Vivo</i>-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins

Alex Preston, Stephen J. Atkinson, Paul Bamborough et al. · Journal of Medicinal Chemistry · 2020 · 53 citations · Full text

, , +14

1–5 of 10